Pharmacokinetic Study of 48-hour Sevoflurane Inhalation Using a Disposable Delivery System (AnaConDa©) in ICU Patients With Acute Kidney Injury

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02042599

Acronym

SEVOKID

Enrollment

Registered

2014-01-23

Start date

2014-01-31

Completion date

2016-03-31

Last updated

2014-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Keywords

Pharmacokinetics, Sevoflurane, Acute kidney injury, Sedation, ICU patients

Brief summary

Describing a pharmacokinetic model of 48-h sevoflurane sedation in ICU patients with acute kidney failure

Detailed description

Prospective clinical monocentric study in ICU with sedated ventilated patients (presenting acute kidney failure) with sevoflurane during 48 h with the AnaConda® system, establishing pharmacokinetic model of sevoflurane and its metabolites (hydroxyfluroisopropanol, fluoride)

Interventions

DRUGSedation with sevoflurane during 48-hr in ICU

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

\- Adult patients ventilated more than 48 h Stable respiratory and hemodynamic conditions Consent of patients or family Arterial line AKIN score = 3

Exclusion criteria

* BMI \<30 Sevoflurane anaphylaxia

Design outcomes

Primary

Measure	Time frame
Determination of plasmatic concentrations of sevoflurane before using AnaConda® system	at 5min, 60 min, 24 hrs and just before the end of sedation.

Secondary

Measure	Time frame
Determination of plasmatic concentrations of HFIP and fluoride	at 5min, 15 min, 60 min and just before the end of sedation. And 5 min, 10 min, 30 min, 120 min and 360 min after the end of sedation

Countries

France

Contacts

Primary ContactPatrick LACARIN

placarin@chu-clermontferrand.fr04 73 75 11 95

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026